The FDA has approved GSK’s Exdensur (depemokimab-ulaa) as an add-on maintenance therapy for adolescents and adults with severe asthma characterized by an eosinophilic phenotype. 1 ...
The FDA has approved Exdensur for add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in patients aged 12 and older.
Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...
May is Asthma Awareness Month, and May 2 is Asthma Awareness Day. This year’s theme is debunking myths and misinformation about asthma. There are many ways you can get involved. Share on Pinterest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback